Blood Test May Predict Dementia in Women Decades Before Symptoms

A simple blood test could potentially identify women at higher risk of developing dementia, even decades before the onset of memory problems, according to research from the University of California San Diego. The test focuses on a blood biomarker that may also help determine which patients would benefit most from preventative treatments.

Identifying Early Risk with p-tau217

The study, published in JAMA Network Open, analyzed data from nearly 3,000 women participating in the Women’s Health Initiative Memory Study over a 25-year period. Researchers discovered that levels of the protein p-tau217 in the blood correlated with an increased risk of dementia. Specifically, women with higher levels of p-tau217 were more likely to develop dementia later in life. JAMA Network Open

Study Details and Findings

The participants, aged 65 to 79 at the start of the study, provided blood samples that were analyzed for p-tau217. The research indicated that the relationship between high p-tau217 levels and cognitive decline was stronger in women over 70 and those with genetic variations linked to Alzheimer’s disease. Interestingly, the biomarker also appeared to be a better predictor of dementia in women who had received hormone therapy with estrogen and progestin during the clinical trial, compared to those who received a placebo.

Confirmation from Barcelona Research

Similar findings emerged from a separate study conducted by the Barcelonaβeta Brain Research Center (BBRC). This research, involving 395 healthy adults (both men and women), demonstrated that detecting p-tau217 in plasma had an 81% accuracy in identifying individuals at risk of Alzheimer’s disease, even before symptoms appeared. El Periódico

Implications for Diagnosis and Treatment

Experts believe this biomarker could significantly improve the diagnosis of dementia and facilitate more efficient preventative measures. While promising, researchers caution that the test needs further refinement before it can be widely implemented in clinical practice. The ability to identify individuals at risk early on is crucial, particularly as clinical trials and novel treatments for Alzheimer’s disease require identifying cases at the earliest stages. JAMA Network

Lifestyle Interventions Show Promise

Alongside biomarker research, studies are also exploring the impact of lifestyle changes on cognitive decline. A recent randomized controlled trial found that intensive multidomain lifestyle interventions—including diet, exercise, and cognitive training—showed significant improvements in cognition and function in patients with mild cognitive impairment or early dementia due to Alzheimer’s disease. PubMed

Key Takeaways

• A blood test measuring the protein p-tau217 may predict dementia risk in women decades before symptoms appear.
• The biomarker’s predictive power is influenced by age and genetic factors.
• Early detection could lead to more effective preventative strategies and targeted treatments.
• Lifestyle interventions show promise in slowing the progression of cognitive decline.